Study Shows Improved Hematocrit, WBC Control With Switch From Hydroxyurea to Ruxolitinib in Polycyth | Cancer Nursing Today
Patients with polycythemia vera who switched from hydroxyurea to ruxolitinib showed improved hematocrit and white blood cell count control, according to an ASH 2024 presentation.